Trian Drops Wendy’s Take-Private Bid Plans, Shares Plunge 14% 
Trump Administration Plans New Drug Pricing Deals With Biotech Firms 
Mercer International Stock Surges 45% on C$20 Million Canada Funding 
BofA Names ASML Top Semiconductor Equipment Pick on Growth, Valuation 
Nvidia Revenue Soars 106% as AI Demand Hits ‘Inflection Point’ 
HP Stock Drops 9% Despite Q3 Earnings Beat and Raised 2026 Outlook 
U.S. Probes Apex Logistics Over Nvidia AI Chip Shipments to China 
Honda, Nissan Eye Shared Vehicle Software Platform by 2029 
BNP Paribas, KB Kookmin Eye $2 Billion Techcombank Stake 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Google Changes EU Spam Policy Amid Antitrust Scrutiny 
Itochu Offers $1.56 Billion to Privatize Dentsu Soken 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
Jefferies Names AMEC Top China Semiconductor Equipment Pick 
OpenAI AI Agent Swarm Behind Hugging Face Hack 
Nvidia Reportedly Eyes $13 Billion Hugging Face Acquisition 
PayPal Shares Sink as $50 Billion Takeover Bid Collapses 
Add as a preferred source on Google
EMERYVILLE, Calif., April 11, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, Gail Farfel, Ph.D., Executive Vice President and Chief Development Officer, and Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and Secretary, will provide a corporate update at the LEERINK Partners CNS Day, being held in New York City on April 18, 2018.
LEERINK Partners CNS Day – Zogenix Presentation Details
Date: Wednesday, April 18, 2018
Time: 2:40 pm Eastern Time / 11:40 am Pacific Time
Location: New York, NY - Convene Conference Center
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at www.ir.zogenix.com.
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
